Clinical Trial Update: A Study to Determine the Safety and Immunogenicity of Bivalent GI.1 and GII.4 Vaccines in Healthy Volunteers [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating safety and immunogenicity of a bivalent GI.1/GII.4 norovirus vaccine in healthy volunteers; results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Norovirus Infection

Drugs mentioned

• Bivalent GI.1/GII.4 Norovirus Vaccine (Bivalent GI.1/GII.4 Norovirus vaccine)

Snippet

Sponsor: Vaxart | Conditions: Norovirus Infections | Phase 2 | Status: COMPLETED | Results posted: 2025-04-15